Roivant Sciences Ltd. Common Shares (ROIV) is a publicly traded Healthcare sector company. As of October 4, 2026, ROIV trades at $35.48 with a market cap of $25.80B and a P/E ratio of -83.81. ROIV moved +0.65% today. Year to date, ROIV is +62.88%; over the trailing twelve months it is +123.53%. Its 52-week range spans $8.73 to $42.50. Analyst consensus is strong buy with an average price target of $47.10. Rallies surfaces ROIV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Roivant President and Immunovant CEO Eric Venker disposes of 200,000 common shares worth $7,324,000: Eric Venker sold 200,000 common shares at a weighted-average price of $36.62 on Sept. 30, 2026, reducing his direct stake to 1,599,154 shares. He also exercised options for 200,000 shares at $3.85.
| Metric | Value |
|---|---|
| Price | $35.48 |
| Market Cap | $25.80B |
| P/E Ratio | -83.81 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $42.50 |
| 52-Week Low | $8.73 |
| Volume | 3.40M |
| Avg Volume | 0 |
| Revenue (TTM) | $8.26M |
| Net Income | $-397.91M |
| Gross Margin | 0.00% |
11 analysts cover ROIV: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $47.10.